0000000000210453

AUTHOR

Aldo Vecchione

showing 2 related works from this author

Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STE…

2011

Introduction: Treatment of elderly patients with small cell lung cancer (SCLC) is based on scanty evidence. Methods: Patients with extensive SCLC, age >70 years, and performance status 0-2 were eligible for a study looking for optimal two-drug combination of gemcitabine (Gem) with vinorelbine (Vin), etoposide (Eto), cisplatin (Cis), or carboplatin (Car). Gemcitabine dose was the same (1000 mg/m2, days 1-8) in all combinations. A two-stage minimax flexible design for response was applied to GemVin combination (Vin 25 mg/m2, days 1-8). For GemCar, GemCis, GemEto, a phase I-II Bayesian design was applied, looking for the optimal dose of the partner drugs. Objective response rate ≥60% and un…

OncologyMaleLung NeoplasmsDeoxycytidineCarboplatinchemistry.chemical_compoundElderlyAntineoplastic Combined Chemotherapy Protocols80 and overCarcinoma Small CellMultivariate AnalysiEtoposideEtoposidePlatinum compoundsAged 80 and overArea under the curveSCLCVinorelbinePrognosisElderly; Etoposide; Gemcitabine; Platinum compounds; SCLC; Vinorelbine; Aged; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma Small Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Humans; Lung Neoplasms; Male; Multivariate Analysis; Prognosis; Proportional Hazards Models; Quality of Life; Treatment Outcome; Vinblastine; VinorelbineTreatment OutcomeOncologyPlatinum compoundToxicityFemalemedicine.drugHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyPrognosiVinorelbineVinblastineDisease-Free SurvivalInternal medicinemedicineHumansAgedProportional Hazards ModelsCisplatinAntineoplastic Combined Chemotherapy ProtocolPerformance statusbusiness.industryCarcinomaSmall CellGemcitabineGemcitabineCarboplatinSurgeryLung NeoplasmchemistryMultivariate AnalysisProportional Hazards ModelQuality of LifeCisplatinbusiness
researchProduct

Early stage human colorectal cancer: prognostic value of nm23-H1 protein overexpression

1997

Nm23 gene codifies for a nucleoside diphosphate kinase allowing the intracellular transduction of the signals. In colorectal cancer nm23 protein expression seems related to the progression of the disease. By immunohistochemistry we have studied the intracytoplasmatic nm23 H1 protein expression in 20 patients affected by colorectal cancer at initial stage. In 12 cases it resulted elevated and in four the disease recurred. The overexpression was not correlated with other prognostic factors. Nm23 H1-positive patients affected by colorectal cancer at initial stage could be considered at risk for disease recurrence and included in a more frequent follow-up protocol.

AdultMaleCancer ResearchPathologymedicine.medical_specialtyColorectal cancerRectumDiseaseMouse model of colorectal and intestinal cancerGene expressionBiomarkers TumormedicineCarcinomaHumansAgedMonomeric GTP-Binding ProteinsNeoplasm StagingAged 80 and overbusiness.industryMiddle AgedNM23 Nucleoside Diphosphate KinasesPrognosismedicine.diseaseNucleoside-diphosphate kinaseNeoplasm Proteinsmedicine.anatomical_structureOncologyNucleoside-Diphosphate KinaseDisease ProgressionCancer researchImmunohistochemistryFemaleColorectal NeoplasmsbusinessTranscription FactorsCancer Letters
researchProduct